Dr Aleksandra Galetin is a Professor of Translational Pharmacokinetics in the Division of Pharmacy & Optometry, School of Health Sciences, and Deputy Director of the Centre for Applied Pharmacokinetic Research (CAPKR, https://www.capkr.manchester.ac.uk/), University of Manchester. In November 2004 she was appointed as a Pfizer Lecturer, following her position as a Postdoctoral Research Associate in the CAPKR. She is the recipient of the 2012 ISSX European New Investigator Award and 2015 AAPS Meritorious Manuscript Award for outstanding achievements in pharmaceutical sciences. In 2016, she had a sabbatical in FDA Office of Clinical Pharmacology where she provided expert advice on PBPK modelling and simulation of drug exposure in specific populations and prediction of DDIs in new drug applications.
She was a member of the ISSX Council (2017-2021) and a chair of the 12th International ISSX Meeting held in Portland, Oregon, July 2019. She will start her term of office as ISSX President-Elect on January 1, 2022 and her role as ISSX President will begin on January 1, 2024.
Prof. Galetin has long standing leadership positions on the expert panels such as International Transporter Consortium (ITC) and AAPS Drug Transport Focus Group Steering Committee (2014-2018). She co-edited a special issue in Clin Pharmacol Ther Nov 2018 dedicated to Advances in the role of drug transporters in drug development. Since 2013, Dr Galetin led/contributed to 9 ITC position papers, defining best practices for the application of endogenous biomarkers and PBPK modelling of transporter-mediated drug-drug interactions (DDI) among others topics.
Prof. Galetin has published more than 110 research papers in highly cited peer reviewed journals (H index 43, >5,500 citations), received numerous invitations to present at international meetings and supervised/mentored over 35 PhD students and postdoctoral research associates.